CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

CADTH pan-Canadian Oncology Drug Review

pCODR RSS feed

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Atezolizumab-Bevacizumab Non-squamous Non-Small Cell Lung Cancer
(Final Recommendation Issued as of July 3, 2020)

Niraparib (Zejula) for Ovarian Cancer
(Open for Feedback on Recommendation until July 17, 2020)

Nivolumab (Opdivo) in combo with Ipilimumab (Yervoy) for Non-Small Cell Lung Cancer
(Open for Input on Submission until July 8, 2020)

Sonidegib (Odomzo) for Basal Cell Carcinoma 
(Open for Input on Submission until July 6, 2020)

Find a Drug Review